查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1984211

器官移植診斷市場：依檢測類型、器官類型、技術、應用和最終用戶分類－2026-2032年全球市場預測

Organ Transplant Diagnostics Market by Test Type, Organ Type, Technology, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 181 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，器官移植診斷市值將達到 107.8 億美元，到 2026 年將成長至 110.6 億美元，到 2032 年將達到 148.5 億美元，複合年成長率為 4.67%。

主要市場統計數據
基準年 2025 107.8億美元
預計年份：2026年 110.6億美元
預測年份 2032 148.5億美元
複合年成長率 (%) 4.67%

器官移植診斷的策略概述：重點關注影響實施的當前臨床重點和營運趨勢

器官移植診斷處於精準醫療、檢查室創新和複雜臨床流程的交會點，及時且準確的檢測決定著移植器官的預後和病患的生存。診斷方法涵蓋基因譜分析、組織學評估、分子監測和血清學檢測，每種方法都具有獨特的臨床價值，從捐贈者選擇到移植後長期監測均有涉及。近年來，臨床實踐既需要高解析度的分子數據，也需要操作簡便，以滿足緊迫的臨床日程安排，這迫使供應商和檢查室重新思考其平台間互通性的策略，並縮短結果報告時間。

技術創新、監管重點和臨床工作流程重組正在重塑移植診斷領域，帶來重大變革。

移植診斷領域正經歷一場變革，其驅動力來自於技術進步、監管改革以及不斷演變的臨床實踐模式的融合。次世代定序和高靈敏度分子檢測提高了診斷準確性的標準，實現了更精準的供受者匹配，並能更早發現排斥反應和感染疾病。同時，檢測自動化和數位化報告技術的進步減少了人工操作，縮短了臨床決策週期，使移植團隊能夠根據檢查室提供的及時資訊重新設計工作流程。

預測美國關稅政策變化對診斷供應鏈、籌資策略和臨床實踐准入的累積影響。

改變關稅結構的政策措施會對診斷平台和耗材的可用性、成本基礎和籌資策略產生重大影響，尤其會對依賴專業檢測和國際供應鏈的移植項目造成顯著衝擊。關稅上調時，檢查室和醫院通常會尋找替代供應商、透過集中採購整合採購，或加快本地相容試劑和設備的檢驗。相反，關稅政策的降低或澄清通常能夠恢復可預測的採購前置作業時間，並鼓勵對先前因成本不確定性而推遲的平台升級進行投資。

詳細的細分見解，將診斷方式、器官特定工作流程、底層技術、臨床應用和最終使用者能力連結起來。

精細化的細分方法揭示了每種檢測類型、器官特異性適應症、底層技術、應用以及最終用戶環境的明確需求促進因素和操作要求。就檢測類型而言，基因檢測（包括DNA定序和SNP基因型鑒定）與組織學相容性工作流程（例如交叉配對試驗和HLA型檢測）有所區別。此外，分子技術（例如次世代定序和PCR）與血清學技術（例如ELISA和流式細胞技術）也有所區別。這些診斷方法與器官特異性要求直接相關，在敏感度、處理能力和結果報告時間等特性方面，心臟、腎臟、肝臟、肺臟和胰臟移植項目各有不同的優先順序。此外，腎臟和肝臟移植計畫也根據腦死捐贈者和活體捐贈者的工作流程進一步細分，從而影響移植前相容性評估和移植後後續觀察的需求。

影響美洲、歐洲、中東、非洲和亞太地區診斷技術引進和傳播的區域趨勢和戰略意義。

區域趨勢對診斷方法的可近性、監管預期和商業策略有顯著影響，美洲、歐洲、中東和非洲以及亞太地區呈現出不同的模式。在美洲，大規模學術移植中心和綜合檢查室網路往往推動高解析度分子檢測的早期應用。同時，在檢體採集方法方面，能夠減輕營運負擔的供應商提供的整合服務解決方案正變得越來越重要。向東北方向的歐洲、中東和非洲地區，由於法律規範和報銷機制的多樣性，供應商需要投入資源來開發針對特定區域的證據和靈活的定價策略，而相關項目則往往更注重互通性和外部品質保證。

競爭格局和企業級策略，結合平台創新、臨床夥伴關係和服務模式來推動採用。

移植診斷生態系統中的主要企業透過整合平台廣度、檢測能力、監管專業知識和服務模式來降低臨床檢查室的進入門檻，從而實現差異化競爭。成熟的平台供應商專注於整合解決方案，將檢測、自動化和數據管理相結合，幫助醫院和參考實驗室簡化檢驗和報告流程。同時，分子診斷領域的專業公司則專注於高解析度HLA型檢測、標靶定序panel和超靈敏排斥反應標記等特色檢測，並經常與臨床檢查室合作進行共同開發和真實世界資料（REW）生成。

為產業領導者提供實用建議，以協調創新、供應鏈韌性和與臨床環境的合作，從而加速技術應用。

產業領導者應優先考慮切實可行的分階段方法，在臨床創新與營運可靠性之間取得平衡，以確保移植項目能夠永續地應用這些技術。首先，應優先開發能夠顯著改善器官分配決策、排斥反應檢測或感染疾病監測的檢測方法，同時將研發投入與具有高影響力的臨床應用案例相結合，並制定嚴格的真實世界檢驗計畫。其次，應透過多元化採購策略和區域製造夥伴關係來加強供應鏈，最大限度地減少外部政策變化的影響，並確保關鍵工作流程所需試劑的持續供應。

透明的調查方法，說明了支持研究結果的資料來源、檢驗方法、分析框架和限制。

本研究整合了對同儕審查的臨床文獻、監管指南文件、技術白皮書和檢驗的檢查室實踐資源的系統性回顧，並輔以來自移植中心、診斷檢查室和器官獲取部門專家的定性意見。分析架構包括移植診斷工作流程的橫斷面流程圖繪製、技術能力比較以及專注於供應鏈和政策波動的情境分析。研究結果透過跨多個資料來源的三角檢驗進行檢驗，以確保其一致性並識別臨床意圖與檢查室操作之間的實際差異。

將優先趨勢、策略挑戰和協作行動進行明確整合，以將診斷創新轉化為臨床成果。

總之，器官移植診斷領域正處於轉捩點。高解析度偵測和改進的營運模式為改善臨床療效提供了清晰的路徑，前提是相關人員能夠解決證據產生、供應保障和工作流程整合等方面的實際限制。技術進步能夠實現更精準的供受者配對和更早發現不利事件，但其應用取決於供應商、檢查室和移植中心能否證明其臨床效用、確保穩定的供應，並將檢測結果整合到特定的診療路徑中。此外，考慮到區域和政策趨勢，還需要根據當地的監管環境和報銷制度，採取個人化的檢驗、定價和分銷方法。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：按檢測類型分類的器官移植診斷市場

  • 基因
    • DNA定序
    • SNP基因基因型鑒定
  • 組織相容性
    • 交叉配對試驗
    • HLA型檢測
  • 分子
    • 次世代定序
    • PCR
  • 血清學
    • ELISA
    • 流式細胞技術

第9章 器官移植診斷市場（依器官分類）

  • 心
  • 腎
    • 腦死捐贈者
    • 活體捐贈者
  • 肝
    • 腦死捐贈者
    • 活體捐贈者
  • 肺
  • 胰臟

第10章 器官移植診斷市場：依技術分類

  • ELISA
    • 競爭性ELISA
    • 夾心ELISA
  • 流式細胞技術
    • 細胞分選
    • 免疫表現型分析
  • 微陣列
    • 表達式數組
    • SNP晶片
  • 次世代定序
    • 目標序列
    • 全基因組定序

第11章 器官移植診斷市場：依應用領域分類

  • 移植後監測
    • 傳染病篩檢
    • 拒收監測
  • 移植前相容性測試
    • 交叉配對試驗
    • HLA相容性檢測

第12章 器官移植診斷市場：依最終使用者分類

  • 診斷中心
    • 醫院檢查室
    • 獨立檢測實驗室
  • 醫院
    • 綜合醫院
    • 移植中心
  • 研究所

第13章 器官移植診斷市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 器官移植診斷市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 器官移植診斷市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國器官移植診斷市場

第17章：中國器官移植診斷市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Abbott Laboratories
  • BAG Diagnostics GmbH
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories, Inc.
  • Biogenuix Medsystems Pvt. Ltd
  • BioMAdvanced Diagnostics
  • Biomerieux SA.
  • Bruker Corporation
  • CareDx Inc.
  • F Hoffman La Roche Ltd.
  • GenDx by Eurobio Scientific
  • Genome Diagnostics BV
  • Hologic Inc.
  • Illumina Inc.
  • Laboratory Corporation of America Holdings
  • Luminex Corporation
  • Omixon Ltd.
  • Oncocyte Corporation
  • Qiagen NV
  • Quest Diagnostics Incorporated
  • Randox Laboratories Ltd.
  • SQI Diagnostics
  • Thermo Fisher Scientific Inc.
  • TransMedics, Inc.
  • Werfen
Product Code: MRR-5C6F41F5B031

The Organ Transplant Diagnostics Market was valued at USD 10.78 billion in 2025 and is projected to grow to USD 11.06 billion in 2026, with a CAGR of 4.67%, reaching USD 14.85 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 10.78 billion
Estimated Year [2026] USD 11.06 billion
Forecast Year [2032] USD 14.85 billion
CAGR (%) 4.67%

Strategic overview of organ transplant diagnostics highlighting current clinical priorities and operational dynamics shaping adoption

Organ transplant diagnostics sit at the intersection of precision medicine, laboratory innovation, and complex clinical workflows, where timely and accurate testing determines graft outcomes and patient survival. Diagnostic modalities span genetic profiling, histocompatibility assessment, molecular surveillance, and serological interrogation, each contributing distinct clinical value from donor selection through long-term posttransplant monitoring. Recent years have seen the clinical community demand both higher resolution molecular data and operational simplicity to fit within tight clinical timelines, driving vendors and laboratories to re-evaluate platform interoperability and result turnaround strategies.

Consequently, clinical and commercial stakeholders must appreciate how testing pathways integrate with transplant program logistics, immunosuppression strategies, and infection surveillance protocols. When interpreted alongside clinical context, test outputs reduce immunologic risk, guide immunomodulation, and improve allocation decisions. As the sector evolves, decision-makers will need to balance novel high-resolution assays and analytics with practical constraints such as laboratory accreditation, reimbursement frameworks, and supply continuity. With these priorities in mind, this executive summary synthesizes the primary inflection points shaping diagnostics adoption, identifies segmentation-driven opportunities, and outlines pragmatic recommendations for leaders aiming to translate evidence into operational advantage.

Critical transformative shifts reshaping transplant diagnostics driven by technological innovation, regulatory focus, and clinical workflow realignment

The landscape of transplant diagnostics is undergoing transformative shifts driven by converging technological advances, regulatory recalibration, and evolving clinical practice patterns. Next-generation sequencing and high-sensitivity molecular assays have raised the bar for diagnostic resolution, enabling more precise donor-recipient matching and earlier detection of rejection or infection. At the same time, improvements in assay automation and digital reporting have reduced manual steps and enabled faster clinical decision cycles, prompting transplant teams to redesign workflows around timely laboratory inputs.

Simultaneously, payers and health systems are emphasizing value-based outcomes, pushing diagnostics suppliers to demonstrate clinical utility through real-world evidence and cost-offset analyses. Regulatory agencies have become more focused on assay standardization and interoperability, which encourages vendors to pursue harmonized protocols and external quality assessment participation. Moreover, supply chain resilience has emerged as a strategic priority, with stakeholders favoring diversified reagent sources and validated contingency plans. Together, these shifts create a market environment where technological differentiation must be matched by evidence generation, supply stability, and operational integration to win adoption across transplant centers and diagnostic laboratories.

Projected cumulative implications of changes in United States tariff policy on diagnostic supply chains, procurement strategies, and clinical access

Policy actions that alter tariff structures can materially affect the availability, cost base, and procurement strategies for diagnostic platforms and consumables, with significant implications for transplant programs that rely on specialized assays and international supply chains. When tariffs increase, laboratories and hospitals often respond by sourcing alternative suppliers, aggregating purchases through centralized procurement, or accelerating local validation of compatible reagents and instruments. Conversely, reductions or clarifications in tariff policy typically restore predictable procurement lead times and support investment in platform upgrades that were previously deferred due to cost uncertainty.

In practice, the cumulative impact on transplant diagnostics includes shifts in inventory management practices, a reassessment of supplier contracts to include tariff-related clauses, and renewed emphasis on regional manufacturing partnerships to insulate critical supply lines. Importantly, diagnostic decision-makers must also consider indirect effects: tariff-induced cost pressures can slow validation of new assays, compress margins for specialized testing providers, and influence decisions about onshoring versus continued international sourcing. To mitigate operational disruption, clinical laboratories and hospital systems should strengthen supply chain visibility, renegotiate terms to include service-level protections, and prioritize diverse vendor ecosystems that reduce exposure to single-source tariff shocks.

Granular segmentation insights connecting diagnostic modalities, organ-specific workflows, enabling technologies, clinical applications, and end-user capabilities

A nuanced segmentation approach reveals distinct demand drivers and operational imperatives across test types, organ indications, enabling technologies, applications, and end-user settings. Test type distinctions separate genetic assays that include DNA sequencing and SNP genotyping from histocompatibility workflows such as crossmatching and HLA typing, and further differentiate molecular methods like next-generation sequencing and PCR from serological techniques including ELISA and flow cytometry. These diagnostic modalities map directly to organ-specific requirements, where heart, kidney, liver, lung, and pancreas programs prioritize different sensitivity, throughput, and turnaround characteristics; kidney and liver programs further bifurcate based on deceased donor and living donor workflows, affecting pretransplant matching and posttransplant surveillance needs.

From a technology vantage, ELISA and flow cytometry remain foundational for many laboratories, while microarray platforms, targeted or whole genome sequencing, and advanced PCR variants support deeper immunogenetic profiling. Application-wise, pretransplant matching activities such as crossmatch testing and HLA matching demand rapid, high-specificity outputs to inform allocation, whereas posttransplant monitoring focuses on infection screening and rejection surveillance that require longitudinal sampling and reliable quantitation. End-user ecosystems span diagnostic centers, hospitals, and research laboratories, with sub-segmentation into hospital labs versus independent labs, general hospitals versus specialized transplant centers, and research entities that often drive early adoption of experimental assays. Taken together, this segmentation fabric highlights where investments in automation, data integration, and clinical validation will deliver the greatest operational and clinical return.

Region-specific dynamics and strategic implications across Americas, Europe Middle East & Africa, and Asia-Pacific influencing diagnostic deployment and uptake

Regional dynamics exert a profound influence on diagnostic availability, regulatory expectations, and commercial strategies, with distinct patterns emerging across the Americas, Europe Middle East & Africa, and Asia-Pacific. In the Americas, large academic transplant centers and consolidated laboratory networks tend to drive early adoption of high-resolution molecular assays, while procurement approaches increasingly favor integrated vendor-service solutions that reduce operational burden. Transitioning northeast to Europe Middle East & Africa, regulatory frameworks and reimbursement heterogeneity require vendors to invest in localized evidence generation and flexible pricing strategies, and programs often place a premium on interoperability and external quality assurance.

Across Asia-Pacific, rapid investment in hospital infrastructure and expanding transplant programs create high growth potential for both centralized and decentralized testing models, yet regional supply chain considerations and local regulatory variations necessitate adaptive go-to-market approaches. Collectively, these regional patterns underscore the importance of tailored market engagement, region-specific validation data, and collaborative partnerships with leading transplant centers to accelerate clinical acceptance and ensure sustainable service delivery.

Competitive landscape and company-level strategies that combine platform innovation, clinical partnerships, and service models to drive adoption

Leading companies in the transplant diagnostics ecosystem differentiate through a combination of platform breadth, assay performance, regulatory expertise, and service models that reduce implementation friction for clinical laboratories. Established platform vendors emphasize integrated solutions that bundle assays, automation, and data management, enabling hospitals and reference laboratories to streamline validation and reporting. At the same time, specialist molecular innovators focus on niche assays such as high-resolution HLA typing, targeted sequencing panels, and ultra-sensitive rejection markers, often partnering with clinical laboratories for co-development and real-world evidence generation.

Beyond product innovation, successful players invest in supply chain resilience, local technical support, and clear clinical utility narratives that resonate with transplant programs and payers. Strategic partnerships between vendors and transplant centers accelerate adoption through early access programs and collaborative studies, while contract laboratory networks and diagnostic service providers expand reach by offering scalable testing capacity. Finally, companies that prioritize interoperable data solutions and actionable reporting formats create stickiness with clinical teams, as these capabilities directly support faster clinical decisions and better patient outcomes.

Actionable recommendations for industry leaders to synchronize innovation, supply resilience, and clinical engagement to accelerate adoption

Industry leaders should prioritize a pragmatic, phased approach that balances clinical innovation with operational reliability to secure sustained adoption across transplant programs. First, align R&D investments with high-impact clinical use cases, prioritizing assays that demonstrably improve allocation decisions, rejection detection, or infection surveillance while planning rigorous real-world validation. Next, fortify supply chains through multi-sourcing strategies and regional manufacturing partnerships to minimize exposure to external policy shocks and ensure ongoing reagent availability for critical workflows.

Concurrently, invest in seamless data integration and reporting standards that reduce cognitive load for transplant clinicians and support multi-center comparability. Commercial teams should pursue collaborative evidence generation with leading transplant centers and design flexible commercial models that accommodate hospital purchasing cycles and laboratory accreditation requirements. Finally, develop modular service offerings that combine training, technical support, and outcome-tracking to facilitate rapid implementation and continuous improvement, thereby converting clinical proof points into long-term programmatic adoption.

Transparent research methodology describing data sources, validation approaches, analytical frameworks, and limitations informing the insights

This research synthesizes insights from a structured review of peer-reviewed clinical literature, regulatory guidance documents, technical white papers, and validated laboratory practice resources, supplemented by qualitative inputs from subject matter experts across transplant centers, diagnostic laboratories, and procurement functions. Analytical frameworks included cross-sectional process mapping of transplant diagnostic workflows, technology capability comparisons, and scenario analysis focused on supply chain and policy perturbations. Findings were validated through triangulation across diverse data sources to ensure consistency and to identify points of practical divergence between clinical intent and laboratory operations.

Limitations include variability in publicly available performance metrics for proprietary assays and heterogeneity in reporting practices across centers, which the methodology seeks to mitigate by emphasizing reproducible decision criteria and transparent assumptions. Where primary data gaps remained, expert consultations helped contextualize likely operational impacts and adoption barriers. This approach yields an actionable synthesis that balances rigor with practical relevance for stakeholders involved in diagnostic selection, laboratory implementation, and clinical program design.

Conclusive synthesis of priority trends, strategic imperatives, and collaborative actions to translate diagnostic innovation into clinical outcomes

In sum, the organ transplant diagnostics domain is at an inflection point where higher-resolution assays and improved operational models offer clear paths to better clinical outcomes, provided stakeholders address practical constraints around evidence generation, supply resilience, and workflow integration. Technological advances enable more precise donor-recipient matching and earlier detection of adverse events, but adoption depends on the ability of vendors, laboratories, and transplant centers to demonstrate clinical utility, ensure consistent supply, and embed testing outputs into actionable care pathways. Moreover, regional and policy dynamics require tailored approaches to validation, pricing, and distribution that respect local regulatory and reimbursement landscapes.

As decision-makers evaluate opportunities, the emphasis should remain on multi-stakeholder collaboration: aligning clinical scientists, laboratory leaders, procurement officers, and industry partners to pilot, validate, and scale diagnostic solutions that improve patient care. By doing so, stakeholders can translate technological promise into measurable clinical impact and sustainable operational models that support transplant programs now and into the future.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Organ Transplant Diagnostics Market, by Test Type

  • 8.1. Genetic
    • 8.1.1. Dna Sequencing
    • 8.1.2. SnP Genotyping
  • 8.2. Histocompatibility
    • 8.2.1. Crossmatching
    • 8.2.2. Hla Typing
  • 8.3. Molecular
    • 8.3.1. Next Generation Sequencing
    • 8.3.2. PCR
  • 8.4. Serological
    • 8.4.1. Elisa
    • 8.4.2. Flow Cytometry

9. Organ Transplant Diagnostics Market, by Organ Type

  • 9.1. Heart
  • 9.2. Kidney
    • 9.2.1. Deceased Donor
    • 9.2.2. Living Donor
  • 9.3. Liver
    • 9.3.1. Deceased Donor
    • 9.3.2. Living Donor
  • 9.4. Lung
  • 9.5. Pancreas

10. Organ Transplant Diagnostics Market, by Technology

  • 10.1. Elisa
    • 10.1.1. Competitive Elisa
    • 10.1.2. Sandwich Elisa
  • 10.2. Flow Cytometry
    • 10.2.1. Cell Sorting
    • 10.2.2. Immunophenotyping
  • 10.3. Microarray
    • 10.3.1. Expression Arrays
    • 10.3.2. SnP Arrays
  • 10.4. Next Generation Sequencing
    • 10.4.1. Targeted Sequencing
    • 10.4.2. Whole Genome Sequencing

11. Organ Transplant Diagnostics Market, by Application

  • 11.1. Posttransplant Monitoring
    • 11.1.1. Infection Screening
    • 11.1.2. Rejection Monitoring
  • 11.2. Pretransplant Matching
    • 11.2.1. Crossmatch Testing
    • 11.2.2. Hla Matching

12. Organ Transplant Diagnostics Market, by End User

  • 12.1. Diagnostic Centers
    • 12.1.1. Hospital Labs
    • 12.1.2. Independent Labs
  • 12.2. Hospitals
    • 12.2.1. General Hospitals
    • 12.2.2. Transplant Centers
  • 12.3. Research Laboratories

13. Organ Transplant Diagnostics Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Organ Transplant Diagnostics Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Organ Transplant Diagnostics Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Organ Transplant Diagnostics Market

17. China Organ Transplant Diagnostics Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Abbott Laboratories
  • 18.6. BAG Diagnostics GmbH
  • 18.7. Becton, Dickinson and Company
  • 18.8. Bio-Rad Laboratories, Inc.
  • 18.9. Biogenuix Medsystems Pvt. Ltd
  • 18.10. BioMAdvanced Diagnostics
  • 18.11. Biomerieux SA.
  • 18.12. Bruker Corporation
  • 18.13. CareDx Inc.
  • 18.14. F Hoffman La Roche Ltd.
  • 18.15. GenDx by Eurobio Scientific
  • 18.16. Genome Diagnostics B.V.
  • 18.17. Hologic Inc.
  • 18.18. Illumina Inc.
  • 18.19. Laboratory Corporation of America Holdings
  • 18.20. Luminex Corporation
  • 18.21. Omixon Ltd.
  • 18.22. Oncocyte Corporation
  • 18.23. Qiagen N.V.
  • 18.24. Quest Diagnostics Incorporated
  • 18.25. Randox Laboratories Ltd.
  • 18.26. SQI Diagnostics
  • 18.27. Thermo Fisher Scientific Inc.
  • 18.28. TransMedics, Inc.
  • 18.29. Werfen

LIST OF FIGURES

  • FIGURE 1. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY ORGAN TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY GENETIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY GENETIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY GENETIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY GENETIC, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY DNA SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY DNA SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY DNA SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY SNP GENOTYPING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY SNP GENOTYPING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY SNP GENOTYPING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HISTOCOMPATIBILITY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HISTOCOMPATIBILITY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HISTOCOMPATIBILITY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HISTOCOMPATIBILITY, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY CROSSMATCHING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY CROSSMATCHING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY CROSSMATCHING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HLA TYPING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HLA TYPING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HLA TYPING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY MOLECULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY MOLECULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY MOLECULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY MOLECULAR, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY PCR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY PCR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY PCR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY SEROLOGICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY SEROLOGICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY SEROLOGICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY SEROLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY ELISA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY ELISA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY ELISA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY FLOW CYTOMETRY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY FLOW CYTOMETRY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY FLOW CYTOMETRY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY ORGAN TYPE, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HEART, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HEART, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HEART, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY KIDNEY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY KIDNEY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY KIDNEY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY KIDNEY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY DECEASED DONOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY DECEASED DONOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY DECEASED DONOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY LIVING DONOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY LIVING DONOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY LIVING DONOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY LIVER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY LIVER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY LIVER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY LIVER, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY DECEASED DONOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY DECEASED DONOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY DECEASED DONOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY LIVING DONOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY LIVING DONOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY LIVING DONOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY LUNG, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY LUNG, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY LUNG, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY PANCREAS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY PANCREAS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY PANCREAS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY ELISA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY ELISA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY ELISA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY ELISA, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY COMPETITIVE ELISA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY COMPETITIVE ELISA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY COMPETITIVE ELISA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY SANDWICH ELISA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY SANDWICH ELISA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY SANDWICH ELISA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY FLOW CYTOMETRY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY FLOW CYTOMETRY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY FLOW CYTOMETRY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY FLOW CYTOMETRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY CELL SORTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY CELL SORTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY CELL SORTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY IMMUNOPHENOTYPING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY IMMUNOPHENOTYPING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY IMMUNOPHENOTYPING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY MICROARRAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY MICROARRAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY MICROARRAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY MICROARRAY, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY EXPRESSION ARRAYS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY EXPRESSION ARRAYS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY EXPRESSION ARRAYS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY SNP ARRAYS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY SNP ARRAYS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY SNP ARRAYS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY TARGETED SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY TARGETED SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY TARGETED SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY POSTTRANSPLANT MONITORING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY POSTTRANSPLANT MONITORING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY POSTTRANSPLANT MONITORING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY POSTTRANSPLANT MONITORING, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY INFECTION SCREENING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY INFECTION SCREENING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY INFECTION SCREENING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY REJECTION MONITORING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY REJECTION MONITORING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY REJECTION MONITORING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY PRETRANSPLANT MATCHING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY PRETRANSPLANT MATCHING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY PRETRANSPLANT MATCHING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY PRETRANSPLANT MATCHING, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY CROSSMATCH TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY CROSSMATCH TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY CROSSMATCH TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HLA MATCHING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HLA MATCHING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HLA MATCHING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC CENTERS, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HOSPITAL LABS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HOSPITAL LABS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 142. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HOSPITAL LABS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY INDEPENDENT LABS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY INDEPENDENT LABS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 145. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY INDEPENDENT LABS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 147. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 148. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 149. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 150. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY GENERAL HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 151. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY GENERAL HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 152. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY GENERAL HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 153. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY TRANSPLANT CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 154. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY TRANSPLANT CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 155. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY TRANSPLANT CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 156. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY RESEARCH LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 157. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY RESEARCH LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 158. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY RESEARCH LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 159. GLOBAL ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 160. AMERICAS ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 161. AMERICAS ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 162. AMERICAS ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY GENETIC, 2018-2032 (USD MILLION)
  • TABLE 163. AMERICAS ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HISTOCOMPATIBILITY, 2018-2032 (USD MILLION)
  • TABLE 164. AMERICAS ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY MOLECULAR, 2018-2032 (USD MILLION)
  • TABLE 165. AMERICAS ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY SEROLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 166. AMERICAS ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY ORGAN TYPE, 2018-2032 (USD MILLION)
  • TABLE 167. AMERICAS ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY KIDNEY, 2018-2032 (USD MILLION)
  • TABLE 168. AMERICAS ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY LIVER, 2018-2032 (USD MILLION)
  • TABLE 169. AMERICAS ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 170. AMERICAS ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY ELISA, 2018-2032 (USD MILLION)
  • TABLE 171. AMERICAS ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY FLOW CYTOMETRY, 2018-2032 (USD MILLION)
  • TABLE 172. AMERICAS ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY MICROARRAY, 2018-2032 (USD MILLION)
  • TABLE 173. AMERICAS ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 174. AMERICAS ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 175. AMERICAS ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY POSTTRANSPLANT MONITORING, 2018-2032 (USD MILLION)
  • TABLE 176. AMERICAS ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY PRETRANSPLANT MATCHING, 2018-2032 (USD MILLION)
  • TABLE 177. AMERICAS ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 178. AMERICAS ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC CENTERS, 2018-2032 (USD MILLION)
  • TABLE 179. AMERICAS ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 180. NORTH AMERICA ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 181. NORTH AMERICA ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 182. NORTH AMERICA ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY GENETIC, 2018-2032 (USD MILLION)
  • TABLE 183. NORTH AMERICA ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HISTOCOMPATIBILITY, 2018-2032 (USD MILLION)
  • TABLE 184. NORTH AMERICA ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY MOLECULAR, 2018-2032 (USD MILLION)
  • TABLE 185. NORTH AMERICA ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY SEROLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 186. NORTH AMERICA ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY ORGAN TYPE, 2018-2032 (USD MILLION)
  • TABLE 187. NORTH AMERICA ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY KIDNEY, 2018-2032 (USD MILLION)
  • TABLE 188. NORTH AMERICA ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY LIVER, 2018-2032 (USD MILLION)
  • TABLE 189. NORTH AMERICA ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 190. NORTH AMERICA ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY ELISA, 2018-2032 (USD MILLION)
  • TABLE 191. NORTH AMERICA ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY FLOW CYTOMETRY, 2018-2032 (USD MILLION)
  • TABLE 192. NORTH AMERICA ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY MICROARRAY, 2018-2032 (USD MILLION)
  • TABLE 193. NORTH AMERICA ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 194. NORTH AMERICA ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 195. NORTH AMERICA ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY POSTTRANSPLANT MONITORING, 2018-2032 (USD MILLION)
  • TABLE 196. NORTH AMERICA ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY PRETRANSPLANT MATCHING, 2018-2032 (USD MILLION)
  • TABLE 197. NORTH AMERICA ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 198. NORTH AMERICA ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC CENTERS, 2018-2032 (USD MILLION)
  • TABLE 199. NORTH AMERICA ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 200. LATIN AMERICA ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 201. LATIN AMERICA ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 202. LATIN AMERICA ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY GENETIC, 2018-2032 (USD MILLION)
  • TABLE 203. LATIN AMERICA ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HISTOCOMPATIBILITY, 2018-2032 (USD MILLION)
  • TABLE 204. LATIN AMERICA ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY MOLECULAR, 2018-2032 (USD MILLION)
  • TABLE 205. LATIN AMERICA ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY SEROLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 206. LATIN AMERICA ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY ORGAN TYPE, 2018-2032 (USD MILLION)
  • TABLE 207. LATIN AMERICA ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY KIDNEY, 2018-2032 (USD MILLION)
  • TABLE 208. LATIN AMERICA ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY LIVER, 2018-2032 (USD MILLION)
  • TABLE 209. LATIN AMERICA ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 210. LATIN AMERICA ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY ELISA, 2018-2032 (USD MILLION)
  • TABLE 211. LATIN AMERICA ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY FLOW CYTOMETRY, 2018-2032 (USD MILLION)
  • TABLE 212. LATIN AMERICA ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY MICROARRAY, 2018-2032 (USD MILLION)
  • TABLE 213. LATIN AMERICA ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 214. LATIN AMERICA ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 215. LATIN AMERICA ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY POSTTRANSPLANT MONITORING, 2018-2032 (USD MILLION)
  • TABLE 216. LATIN AMERICA ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY PRETRANSPLANT MATCHING, 2018-2032 (USD MILLION)
  • TABLE 217. LATIN AMERICA ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 218. LATIN AMERICA ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC CENTERS, 2018-2032 (USD MILLION)
  • TABLE 219. LATIN AMERICA ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 220. EUROPE, MIDDLE EAST & AFRICA ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 221. EUROPE, MIDDLE EAST & AFRICA ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 222. EUROPE, MIDDLE EAST & AFRICA ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY GENETIC, 2018-2032 (USD MILLION)
  • TABLE 223. EUROPE, MIDDLE EAST & AFRICA ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HISTOCOMPATIBILITY, 2018-2032 (USD MILLION)
  • TABLE 224. EUROPE, MIDDLE EAST & AFRICA ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY MOLECULAR, 2018-2032 (USD MILLION)
  • TABLE 225. EUROPE, MIDDLE EAST & AFRICA ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY SEROLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 226. EUROPE, MIDDLE EAST & AFRICA ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY ORGAN TYPE, 2018-2032 (USD MILLION)
  • TABLE 227. EUROPE, MIDDLE EAST & AFRICA ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY KIDNEY, 2018-2032 (USD MILLION)
  • TABLE 228. EUROPE, MIDDLE EAST & AFRICA ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY LIVER, 2018-2032 (USD MILLION)
  • TABLE 229. EUROPE, MIDDLE EAST & AFRICA ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 230. EUROPE, MIDDLE EAST & AFRICA ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY ELISA, 2018-2032 (USD MILLION)
  • TABLE 231. EUROPE, MIDDLE EAST & AFRICA ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY FLOW CYTOMETRY, 2018-2032 (USD MILLION)
  • TABLE 232. EUROPE, MIDDLE EAST & AFRICA ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY MICROARRAY, 2018-2032 (USD MILLION)
  • TABLE 233. EUROPE, MIDDLE EAST & AFRICA ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 234. EUROPE, MIDDLE EAST & AFRICA ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 235. EUROPE, MIDDLE EAST & AFRICA ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY POSTTRANSPLANT MONITORING, 2018-2032 (USD MILLION)
  • TABLE 236. EUROPE, MIDDLE EAST & AFRICA ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY PRETRANSPLANT MATCHING, 2018-2032 (USD MILLION)
  • TABLE 237. EUROPE, MIDDLE EAST & AFRICA ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 238. EUROPE, MIDDLE EAST & AFRICA ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC CENTERS, 2018-2032 (USD MILLION)
  • TABLE 239. EUROPE, MIDDLE EAST & AFRICA ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 240. EUROPE ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 241. EUROPE ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 242. EUROPE ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY GENETIC, 2018-2032 (USD MILLION)
  • TABLE 243. EUROPE ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HISTOCOMPATIBILITY, 2018-2032 (USD MILLION)
  • TABLE 244. EUROPE ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY MOLECULAR, 2018-2032 (USD MILLION)
  • TABLE 245. EUROPE ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY SEROLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 246. EUROPE ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY ORGAN TYPE, 2018-2032 (USD MILLION)
  • TABLE 247. EUROPE ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY KIDNEY, 2018-2032 (USD MILLION)
  • TABLE 248. EUROPE ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY LIVER, 2018-2032 (USD MILLION)
  • TABLE 249. EUROPE ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 250. EUROPE ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY ELISA, 2018-2032 (USD MILLION)
  • TABLE 251. EUROPE ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY FLOW CYTOMETRY, 2018-2032 (USD MILLION)
  • TABLE 252. EUROPE ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY MICROARRAY, 2018-2032 (USD MILLION)
  • TABLE 253. EUROPE ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 254. EUROPE ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 255. EUROPE ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY POSTTRANSPLANT MONITORING, 2018-2032 (USD MILLION)
  • TABLE 256. EUROPE ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY PRETRANSPLANT MATCHING, 2018-2032 (USD MILLION)
  • TABLE 257. EUROPE ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 258. EUROPE ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC CENTERS, 2018-2032 (USD MILLION)
  • TABLE 259. EUROPE ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 260. MIDDLE EAST ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 261. MIDDLE EAST ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 262. MIDDLE EAST ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY GENETIC, 2018-2032 (USD MILLION)
  • TABLE 263. MIDDLE EAST ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HISTOCOMPATIBILITY, 2018-2032 (USD MILLION)
  • TABLE 264. MIDDLE EAST ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY MOLECULAR, 2018-2032 (USD MILLION)
  • TABLE 265. MIDDLE EAST ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY SEROLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 266. MIDDLE EAST ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY ORGAN TYPE, 2018-2032 (USD MILLION)
  • TABLE 267. MIDDLE EAST ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY KIDNEY, 2018-2032 (USD MILLION)
  • TABLE 268. MIDDLE EAST ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY LIVER, 2018-2032 (USD MILLION)
  • TABLE 269. MIDDLE EAST ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 270. MIDDLE EAST ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY ELISA, 2018-2032 (USD MILLION)
  • TABLE 271. MIDDLE EAST ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY FLOW CYTOMETRY, 2018-2032 (USD MILLION)
  • TABLE 272. MIDDLE EAST ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY MICROARRAY, 2018-2032 (USD MILLION)
  • TABLE 273. MIDDLE EAST ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 274. MIDDLE EAST ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 275. MIDDLE EAST ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY POSTTRANSPLANT MONITORING, 2018-2032 (USD MILLION)
  • TABLE 276. MIDDLE EAST ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY PRETRANSPLANT MATCHING, 2018-2032 (USD MILLION)
  • TABLE 277. MIDDLE EAST ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 278. MIDDLE EAST ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC CENTERS, 2018-2032 (USD MILLION)
  • TABLE 279. MIDDLE EAST ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 280. AFRICA ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 281. AFRICA ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 282. AFRICA ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY GENETIC, 2018-2032 (USD MILLION)
  • TABLE 283. AFRICA ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HISTOCOMPATIBILITY, 2018-2032 (USD MILLION)
  • TABLE 284. AFRICA ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY MOLECULAR, 2018-2032 (USD MILLION)
  • TABLE 285. AFRICA ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY SEROLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 286. AFRICA ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY ORGAN TYPE, 2018-2032 (USD MILLION)
  • TABLE 287. AFRICA ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY KIDNEY, 2018-2032 (USD MILLION)
  • TABLE 288. AFRICA ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY LIVER, 2018-2032 (USD MILLION)
  • TABLE 289. AFRICA ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 290. AFRICA ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY ELISA, 2018-2032 (USD MILLION)
  • TABLE 291. AFRICA ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY FLOW CYTOMETRY, 2018-2032 (USD MILLION)
  • TABLE 292. AFRICA ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY MICROARRAY, 2018-2032 (USD MILLION)
  • TABLE 293. AFRICA ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 294. AFRICA ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 295. AFRICA ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY POSTTRANSPLANT MONITORING, 2018-2032 (USD MILLION)
  • TABLE 296. AFRICA ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY PRETRANSPLANT MATCHING, 2018-2032 (USD MILLION)
  • TABLE 297. AFRICA ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 298. AFRICA ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC CENTERS, 2018-2032 (USD MILLION)
  • TABLE 299. AFRICA ORGAN TRANSPLANT DIAGNOSTICS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 300. ASIA-PACIFIC ORGAN TRANSPLANT DIAGNOSTICS MARKE